Spyre Therapeutics, Inc. Common Stock (SYRE) is a publicly traded Healthcare sector company. As of May 21, 2026, SYRE trades at $71.54 with a market cap of $6.09B and a P/E ratio of 0.00. SYRE moved +7.99% today. Year to date, SYRE is +140.05%; over the trailing twelve months it is +367.01%. Its 52-week range spans $10.91 to $78.80. Analyst consensus is strong buy with an average price target of $95.86. Rallies surfaces SYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes SYRE SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $71.54 |
| Market Cap | $6.09B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $78.80 |
| 52-Week Low | $10.91 |
| Volume | 542 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-155.20M |
| Gross Margin | 0.00% |
16 analysts cover SYRE: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.86.